Ariad Pharmaceuticals Inc – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 06/30/16 Q2 2016 – amended

ended 09/30/16 Q3

ended 06/30/16 Q2

ended 03/31/16 Q1

ended 12/31/15 FY 2015 – amended

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals Inc

Westfield Capital Management Co LP

Sarissa Capital Management LP

Third party tender offer – amended

News Filter

Notice of Increased Conversion Rate and Supplemental Indenture

Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

Takeda to Acquire ARIAD Pharmaceuticals, Inc

Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients With CNS Metastases at the World Conference on Lung Cancer

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Definitive proxy

Additional info about upcoming vote

Other Filter

Confidential treatment order

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No action letter